Par Drugs and Chemicals LimitedPARCorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Jun 2026 14 quarters of data

₹109.53

MCap ₹135 Cr · P/E 9.3

Par Drugs and Chemicals Limited — Stock analysis & AI research Par Drugs and Chemicals Limited — Seasonality — best & worst months Par Drugs and Chemicals Limited — Technical setup — score, trend, support & resistance Par Drugs and Chemicals Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹31 Cr

Sales · Jun 2026

+20.1% YoY

₹6 Cr

Operating Profit · Jun 2026

+79.2% YoY

20.4%

OPM % · Jun 2026

+48.9% YoY

₹5 Cr

Net Profit · Jun 2026

+41.6% YoY

₹3.83

EPS · Jun 2026

+41.9% YoY

📝 Par Drugs and Chemicals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Par Drugs and Chemicals Limited reported revenue of ₹31 crore for the quarter ended June 2026 (Q1 FY27), up 20.1% from ₹26 crore in the same quarter last year, and up 59.5% sequentially over the March 2026 quarter.

Net profit rose 41.6% year-on-year to ₹5 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹3.83.

Operating profit stood at ₹6 crore — an operating margin (OPM) of 20.4%, compared with 13.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Par Drugs and Chemicals Limited posted revenue of ₹104 crore, a growth of 2.7% over FY25, with a net profit of ₹13 crore (down 1.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹109 crore with a net profit of ₹14 crore.

Valuation snapshot

At the current price of ₹109.53, PAR has a market capitalisation of ₹135 crore and a trailing P/E of about 9.3.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 9th-largest of the 11 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 73.41%, domestic institutional investors (DIIs) 0.09%, public shareholders 26.51% of Par Drugs and Chemicals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹135 Cr

Current Price ?

₹109.5

P/E ?

9.30below ind

Industry P/E ?

32.10

P/B ?

1.20

P/S ?

1.24

P/FCF ?

9.63

Enterprise Value ?

₹135 Cr

EV/EBITDA ?

6.76

PEG ?

1.86

Earnings Yield ?

12.0%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹109 Cr

OPM ?

18.3%

Profit after tax (TTM) ?

₹14 Cr

EPS (TTM) ?

₹11.78

ROCE ?

17.0%

ROE ?

12.9%

ROA ?

11.2%

Growth

Sales — latest qtr ?

₹31 Cr

PAT — latest qtr ?

₹5 Cr

YoY qtr sales growth ?

20.1%

YoY qtr profit growth ?

41.6%

Sales growth (3y) ?

Sales growth (5y) ?

11%

Profit growth (3y) ?

Profit growth (5y) ?

Financial Health

Debt ?

₹0 Cr

Debt to Equity ?

0.00

Interest Coverage ?

106.5

Current Ratio ?

N/A

Ownership

Promoter holding ?

73.41%

Change in promoter holding ?

0.04%

Pledged percentage ?

N/A

Market

Return 3 months ?

4.4%

Return 6 months ?

16.6%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	24	23	26	24	23	23	35	21	22	26	29	29	20	31	+20.1%	+59.5%
Operating Profit	5	4	7	5	6	4	11	1	2	4	6	6	1	6	+79.2%	+343.1%
Other Income	0	0	0	0	-0	0	1	0	1	2	0	1	0	1	-49.1%	+159.8%
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	+31.3%	-46.5%
Depreciation	1	1	1	1	1	1	1	1	1	1	1	1	1	1	+6.7%	+3.7%
Profit Before Tax	5	3	7	5	5	3	11	1	2	4	6	6	1	6	+41.4%	+662.7%
Net Profit	3	2	5	3	4	3	9	1	2	3	4	5	1	5	+41.6%	+454.4%
EPS	2.80	2.01	3.97	2.78	3.02	2.06	6.99	0.47	1.34	2.70	3.36	3.90	0.69	3.83	+41.9%	+455.1%
OPM %	22.0%	18.0%	28.4%	21.8%	26.7%	18.7%	32.9%	6.7%	10.9%	13.7%	21.2%	20.7%	7.3%	20.4%	+48.9%	+179.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹101 Cr	₹104 Cr	₹109 Cr	+2.7%
Operating Profit	₹20 Cr	₹17 Cr	₹20 Cr	-12.2%
OPM %	19.31%	16.53%	18.32%	-14.4%
NPM %	13.23%	12.64%	13.31%	-4.5%
Other Income	₹2 Cr	₹4 Cr	₹3 Cr	+86.0%
Depreciation	₹4 Cr	₹4 Cr	₹4 Cr	+1.6%
Interest	₹0 Cr	₹0 Cr	₹0 Cr	+51.1%
EBIT	₹16 Cr	₹13 Cr	₹16 Cr	-15.3%
PBT	₹18 Cr	₹17 Cr	₹19 Cr	-3.5%
Tax	₹4 Cr	₹4 Cr	₹5 Cr	+7.1%
Net Profit	₹13 Cr	₹13 Cr	₹14 Cr	-1.9%
EPS	₹10.86	₹10.65	₹11.78	-1.9%
Material Cost	₹29 Cr	₹34 Cr	₹35 Cr	+16.7%
Employee Cost	₹4 Cr	₹4 Cr	₹4 Cr	+6.2%
Extraordinary Items	₹0 Cr	₹0 Cr	₹0 Cr	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Reserves	59	73	87	100	+14.9%
Borrowings	0	0	0	0	—
Equity Capital	12	12	12	12	+0.0%
Other Liabilities	18	16	20	17	-15.0%
Total Liabilities	89	102	119	129	+8.4%
Fixed Assets	38	41	39	36	-7.7%
CWIP	0	0	0	1	—
Investments	0	0	25	27	+8.0%
Other Assets	50	60	55	65	+18.2%
Total Assets	89	102	119	129	+8.4%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	13	20	16	16	+0.0%
Cash from Investing Activity	-7	-6	-25	-2	+92.0%
Cash from Financing Activity	0	0	0	0	—
Net Cash Flow	6	14	-9	14	+255.6%
Free Cash Flow	6	14	15	14	-6.7%
CFO/OP	97%	108%	106%	125%	+17.9%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	65	52	60	42	-30.0%
Inventory Days	49	45	58	45	-22.4%
Days Payable	73	58	104	69	-33.7%
Cash Conversion Cycle	40	40	15	19	+26.7%
Working Capital Days	50	40	39	31	-20.5%
ROCE %	23%	25%	18%	17%	-5.6%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	73.37%	73.37%	73.41%	73.41%	73.41%	+0.0%
FIIs	0.00%	0.00%	0.00%	0.00%	—	—
DIIs	0.00%	0.00%	0.00%	0.00%	0.09%	—
Public	26.63%	26.63%	26.59%	26.59%	26.51%	-0.3%
No. of Shareholders	14,887	14,280	13,761	13,222	12,672	-4.2%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SMSPHARMA SMS Pharmaceuticals	₹442.45	4,144	39.7	898	102	19.3%	11.4%	13.3%	48.6%	5.6%	-1.4%
2	AARTIDRUGS Aarti Drugs	₹428.30	3,909	20.5	2,678	191	12.4%	7.1%	7.5%	16.3%	18.9%	-7.2%
3	HIKAL Hikal	₹229.83	2,834	—	1,734	-34	13.4%	-2.0%	-8.0%	-154.4%	6.0%	67.0%
4	BETA Beta Drugs	₹2,064.90	2,084	37.5	513	57	20.5%	11.2%	—	—	25.5%	31.7%
5	NGLFINE NGL Fine-Chem	₹2,786.60	1,722	30.1	536	57	15.6%	10.6%	36.0%	123.2%	33.6%	99.1%
6	ANUHPHR Anuh Pharma	₹92.99	932	21.1	779	44	8.6%	5.7%	16.5%	-12.8%	4.2%	42.8%
7	INFINIUM Infinium Pharma	₹222.95	347	31.2	190	14	11.3%	7.2%	—	—	45.2%	166.7%
8	AAREYDRUGS Aarey Drugs	₹98.71	329	67.1	415	4	1.6%	1.0%	-0.4%	12.3%	-56.3%	-25.3%
9	PAR Par Drugs	₹128.90	159	10.9	109	14	18.3%	13.3%	2.7%	-1.9%	20.1%	41.6%
10	KREBSBIO Krebs Biochemicals	₹57.94	125	—	25	-14	-10.0%	-55.9%	-45.2%	37.1%	27.4%	53.3%
11	VILINBIO Vilin Bio	₹18.00	27	14.2	42	2	7.6%	4.6%	—	—	215.9%	1680.0%

❓ Frequently asked questions

What was Par Drugs and Chemicals Limited's revenue in Q1 FY27?

What was Par Drugs and Chemicals Limited's net profit in Q1 FY27?